6 stories found
Biotech firm Alnylam presented new clinical findings at the European Society of Cardiology 2026 conference, highlighting the efficacy of its RNA interference drugs in treating transthyretin amyloid cardiomyopathy.
Tenax Therapeutics announced it will showcase late-breaking scientific data from its Phase 3 LEVEL clinical trial during upcoming sessions at the European Society of Cardiology Congress.
The pharmaceutical company showcased long-term efficacy and safety results for mavacamten in treating obstructive hypertrophic cardiomyopathy at a major cardiology conference.
CRISPR Therapeutics has presented initial clinical trial results for CTX310, a gene-editing treatment aimed at lowering triglycerides and LDL cholesterol, showing durable genetic modifications at the European Society of Cardiology congress.
Cytokinetics announced additional clinical trial results for its ACACIA-HCM and MAPLE-HCM programs during a late-breaking session at the European Society of Cardiology Congress, advancing treatments for hypertrophic cardiomyopathy.
New analyses from the REDUCE-IT® trial and EPA mechanistic data are scheduled for presentation at the European Society of Cardiology (ESC) Congress in 2026.